Novartis AG ADR (NVS) Social Stream
NOVARTIS AG (NVS) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering NVS.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-10-27 | 7 | $108 | $100 | $104.333 | $102.91 | 1.38% |
| 2022-01-17 | 8 | $105 | $100 | $102.666 | $102.91 | -0.24% |
| 2022-03-08 | 7 | $105 | $100 | $103 | $102.91 | 0.09% |
| 2022-04-13 | 6 | $105 | $100 | $103 | $102.91 | 0.09% |
| 2022-05-16 | 6 | $106 | $100 | $103.666 | $102.91 | 0.73% |
| 2022-08-26 | 6 | $105 | $97 | $101.666 | $102.91 | -1.21% |
| 2022-09-27 | 7 | $105 | $97 | $101.666 | $102.91 | -1.21% |
| 2022-10-25 | 7 | $105 | $97 | $101 | $102.91 | -1.86% |
| 2022-11-21 | 7 | $105 | $92 | $99.333 | $102.91 | -3.48% |
| 2022-12-05 | 7 | $105 | $101 | $102.666 | $102.91 | -0.24% |
| 2022-12-20 | 7 | $107 | $102 | $104.666 | $102.91 | 1.71% |
| 2023-01-16 | 7 | $108 | $102 | $105 | $102.91 | 2.03% |
| 2023-02-17 | 8 | $108 | $102 | $105 | $102.91 | 2.03% |
| 2023-03-27 | 8 | $108 | $102 | $105 | $102.91 | 2.03% |
| 2023-04-18 | 8 | $113.5 | $105 | $108.833 | $102.91 | 5.76% |
| 2023-04-25 | 8 | $113.5 | $105 | $110.166 | $102.91 | 7.05% |
| 2023-04-26 | 8 | $120 | $105 | $112.333 | $102.91 | 9.16% |
| 2023-07-17 | 8 | $120 | $105 | $114 | $102.91 | 10.78% |
| 2023-07-19 | 8 | $124 | $105 | $115.333 | $102.91 | 12.07% |
| 2023-07-23 | 8 | $124 | $105 | $116.666 | $102.91 | 13.37% |
| 2023-09-05 | 8 | $124 | $105 | $116 | $102.91 | 12.72% |
| 2023-09-12 | 8 | $129 | $105 | $117.666 | $102.91 | 14.34% |
The Trend in the Analyst Price Target
NVS's average price target has moved up $11.82 over the prior 34 months.
Over the past 51 weeks, NVS's average upside potential has been 18.19%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-10-25 | 7 | 105.0 | 97 | 101.000 | 78.51 | 28.65% |
| 2023-04-18 | 8 | 113.5 | 105 | 110.166 | 97.32 | 13.2% |
| 2023-04-26 | 8 | 120.0 | 105 | 112.333 | 102.54 | 9.55% |
| 2023-07-05 | 8 | 120.0 | 105 | 114.000 | 98.95 | 15.21% |
| 2023-09-12 | 8 | 129.0 | 105 | 117.666 | 100.66 | 16.89% |
NVS Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 2.25 | 3 | 0 | 5 | 0 | 0 | 8 |
The Trend in the Broker Recommendations
Over the past 17 months, NVS's average broker recommendation rating improved by 0.08.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for NVS as an investment opportunity.
- In terms of how NOVARTIS AG fares relative to all US stocks, note that its variance in analysts' estimates is lower than -70.16% of that group.
- NOVARTIS AG's number of analysts covering the stock is higher than 90.25% of stocks in the mega market cap category.
- NOVARTIS AG's upside potential (average analyst target price relative to current price) is greater than 257.32% of Pharmaceutical Products stocks.
- NOVARTIS AG's average analyst price target is higher than 1975.01% of Pharmaceutical Products stocks.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to NOVARTIS AG are ABBV, MRK, and JNJ.
View All Top Stocks by Price Target
Is NVS a Buy, Hold or Sell? See the POWR Ratings now!